Ping Chang1, Yuping Liao2, Jianbin Guan1, Yuexun Guo1, Ming Zhao3, Jianmin Hu3, Jian Zhou1, Hua Wang1, Zhongran Cen1, Ying Tang1, Zhanguo Liu4. 1. Department of Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou. 2. Department of Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou; Department of Critical Care Medicine, Dongguan People's Hospital, Dongguan. 3. Department of Organ Transplant, Zhujiang Hospital, Southern Medical University, Guangzhou, China. 4. Department of Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou. Electronic address: zhguoliu@163.com.
Abstract
BACKGROUND: Whether hydrocortisone, vitamin C, and thiamine treatment can reduce the mortality of patients with sepsis is controversial. RESEARCH QUESTION: To evaluate the efficacy and safety of hydrocortisone, vitamin C, and thiamine combination treatment for patients with sepsis or septic shock (HYVCTTSSS). STUDY DESIGN AND METHODS: This single-blind, randomized controlled trial evaluated treatment with hydrocortisone (50 mg every 6 h for 7 days), vitamin C (1.5 g every 6 h for 4 days), and thiamine (200 mg every 12 h for 4 days) vs placebo (normal saline) in patients with sepsis. The intention-to-treat analysis was used. Primary outcome was 28-day all-cause mortality, and secondary outcomes were organ protection, procalcitonin reduction, and adverse events related to hydrocortisone, vitamin C, and thiamine. RESULTS:Eighty patients were randomized to receive combination treatment (n = 40) or normal saline (n = 40). No difference in 28-day all-cause mortality was observed (27.5% vs 35%, respectively; P = .47); however, treatment was associated with a significant improvement of 72-h change in Sequential Organ Failure Assessment score (P = .02). In adverse events analysis, the treatment group exhibited more incidents of hypernatremia (P = .005). In prespecified subgroup analysis, patients of the treatment subgroup diagnosed with sepsis within 48 h showed lower mortality than those in the control subgroup (P = .02). The study was terminated after the midterm analysis. INTERPRETATION: Among patients with sepsis or septic shock, the combination of hydrocortisone, vitamin C, and thiamine did not reduce mortality compared with placebo. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT03258684; URL: www.clinicaltrials.gov.
RCT Entities:
BACKGROUND: Whether hydrocortisone, vitamin C, and thiamine treatment can reduce the mortality of patients with sepsis is controversial. RESEARCH QUESTION: To evaluate the efficacy and safety of hydrocortisone, vitamin C, and thiamine combination treatment for patients with sepsis or septic shock (HYVCTTSSS). STUDY DESIGN AND METHODS: This single-blind, randomized controlled trial evaluated treatment with hydrocortisone (50 mg every 6 h for 7 days), vitamin C (1.5 g every 6 h for 4 days), and thiamine (200 mg every 12 h for 4 days) vs placebo (normal saline) in patients with sepsis. The intention-to-treat analysis was used. Primary outcome was 28-day all-cause mortality, and secondary outcomes were organ protection, procalcitonin reduction, and adverse events related to hydrocortisone, vitamin C, and thiamine. RESULTS: Eighty patients were randomized to receive combination treatment (n = 40) or normal saline (n = 40). No difference in 28-day all-cause mortality was observed (27.5% vs 35%, respectively; P = .47); however, treatment was associated with a significant improvement of 72-h change in Sequential Organ Failure Assessment score (P = .02). In adverse events analysis, the treatment group exhibited more incidents of hypernatremia (P = .005). In prespecified subgroup analysis, patients of the treatment subgroup diagnosed with sepsis within 48 h showed lower mortality than those in the control subgroup (P = .02). The study was terminated after the midterm analysis. INTERPRETATION: Among patients with sepsis or septic shock, the combination of hydrocortisone, vitamin C, and thiamine did not reduce mortality compared with placebo. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT03258684; URL: www.clinicaltrials.gov.
Authors: Jan Bakker; Eduardo Kattan; Djillali Annane; Ricardo Castro; Maurizio Cecconi; Daniel De Backer; Arnaldo Dubin; Laura Evans; Michelle Ng Gong; Olfa Hamzaoui; Can Ince; Bruno Levy; Xavier Monnet; Gustavo A Ospina Tascón; Marlies Ostermann; Michael R Pinsky; James A Russell; Bernd Saugel; Thomas W L Scheeren; Jean-Louis Teboul; Antoine Vieillard Baron; Jean-Louis Vincent; Fernando G Zampieri; Glenn Hernandez Journal: Intensive Care Med Date: 2021-12-15 Impact factor: 17.440
Authors: Allan E Stolarski; Jiyoun Kim; Kevin Rop; Katherine Wee; Qiuyang Zhang; Daniel G Remick Journal: J Trauma Acute Care Surg Date: 2022-05-20 Impact factor: 3.697
Authors: Zubair U Mohamed; Pratibha Prasannan; Merlin Moni; Fabia Edathadathil; Preetha Prasanna; Anup Menon; Sabarish Nair; C R Greeshma; Dipu T Sathyapalan; Veena Menon; Vidya Menon Journal: Indian J Crit Care Med Date: 2020-08
Authors: Sander Rozemeijer; Harm-Jan de Grooth; Paul W G Elbers; Armand R J Girbes; Corstiaan A den Uil; Eric A Dubois; Evert-Jan Wils; Thijs C D Rettig; Arthur R H van Zanten; Roel Vink; Bas van den Bogaard; Rob J Bosman; Heleen M Oudemans-van Straaten; Angélique M E de Man Journal: Trials Date: 2021-08-18 Impact factor: 2.279
Authors: Sean S Scholz; Rainer Borgstedt; Nicole Ebeling; Leoni C Menzel; Gerrit Jansen; Sebastian Rehberg Journal: Crit Care Date: 2021-01-06 Impact factor: 9.097
Authors: Sung Yeon Hwang; Seung Mok Ryoo; Jong Eun Park; You Hwan Jo; Dong-Hyun Jang; Gil Joon Suh; Taegyun Kim; Youn-Jung Kim; Seonwoo Kim; Hyun Cho; Ik Joon Jo; Sung Phil Chung; Sung-Hyuk Choi; Tae Gun Shin; Won Young Kim Journal: Intensive Care Med Date: 2020-08-11 Impact factor: 17.440
Authors: Eric L Wald; Colleen M Badke; Lauren K Hintz; Michael Spewak; L Nelson Sanchez-Pinto Journal: Pediatr Res Date: 2021-07-31 Impact factor: 3.756